Why the study?
Vaccination is increasingly recognized for preventing cardiovascular disease in high-risk patients, prompting the need to examine existing evidence and offer practical advice on timing, target demographics, and complex clinical scenarios.
Does vaccination reduce the incidence of major adverse cardiovascular events in high-risk patients with cardiovascular conditions?
Does vaccination reduce the incidence of major adverse cardiovascular events in high-risk patients with cardiovascular conditions?
This ESC clinical consensus statement establishes vaccination as a key preventive measure against major adverse cardiovascular events in high-risk cardiovascular patients.
Answers are grounded in this paper and cite their sources.
Supports influenza vaccination to reduce MACE in high-risk CV patients; leaves open dedicated RCTs for other vaccines.
Vaccination is increasingly acknowledged as an effective preventive measure not only against specific infections, but also for the prevention of cardiovascular disease in high-risk patients. Specifically, a growing body of evidence suggests that vaccines against influenza, SARS-CoV-2, respiratory syncytial virus, herpes zoster, and other viruses significantly reduce infection and for influenza the incidence of major adverse cardiovascular events in vaccinated individuals. This clinical consensus statement examines the existing literature and accumulated evidence and offers practical clinical advice on vaccination timing and target demographics, specifically addressing complex clinical scenarios with a focus on cardiovascular conditions. It includes guidelines for vaccinating vulnerable populations such as immunosuppressed individuals, patients with congenital heart disease, and pregnant women as well as safety and potential complications of the procedure.
No takes yet. Share an insight, caveat, or question.
Heidecker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: